A meta-analysis of patient-level data from three randomized controlled trials involving patients with newly diagnosed multiple myeloma indicates that lenalidomide maintenance therapy significantly improves the outcomes of patients undergoing autologous stem-cell transplantation (ASCT). In this analysis, patients receiving lenalidomide had a median progression-free survival duration of 52.8 months versus only 23.5 months in the placebo group. These findings confirm the value of lenalidomide maintenance in this setting.